All In Biotech

Drug Trial Radar · NCT05076617

A Study to Test the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures

An Open-Label, Multicenter, Outpatient Extension Study to Evaluate the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitationPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Enrolling by invitation

Enrollment

300

Planned (sponsor's estimate)

Start

Feb 3, 2022

Primary completion

Nov 30, 2028

Study completion Nov 30, 2028

Sponsor

Lead sponsor
UCB Biopharma SRLUCB
Sponsor type
Industry
First posted
Oct 13, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the long-term safety and tolerability of Staccato alprazolam.

Conditions

  • Stereotypical Prolonged Seizures

Interventions

  • Staccato alprazolamDrug

    * Pharmaceutical form: Inhalation powder * Route of administration: Inhalation Participants will receive Staccato alprazolam during the Treatment Period.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency of treatment-emergent adverse events (TEAEs)Time frame: From Baseline up to the End of Study Visit (up to 78 months)
  2. Frequency of TEAEs leading to withdrawal from studyTime frame: From Baseline up to the End of Study Visit (up to 78 months)
  3. Frequency of serious TEAEsTime frame: From Baseline up to the End of Study Visit (up to 78 months)

Locations

133 sites in 12 countries. Site status is shown where the registry gives one.

  • Ep0165 50506

    Phoenix, Arizona

  • Ep0165 50720

    Scottsdale, Arizona

  • Ep0165 50118

    Downey, California

  • Ep0165 50416

    La Jolla, California

  • Ep0165 50702

    Long Beach, California

  • Ep0165 50716

    Sacramento, California

  • Ep0165 50088

    Washington D.C., District of Columbia

  • Ep0165 50515

    Gulf Breeze, Florida

  • Ep0165 50508

    Jacksonville, Florida

  • Ep0165 50342

    Jacksonville, Florida

  • Ep0165 50199

    Miami, Florida

  • Ep0165 50676

    Miami, Florida

  • Ep0165 50509

    Orlando, Florida

  • Ep0165 50703

    Rockledge, Florida

  • Ep0165 50308

    Tampa, Florida

  • Ep0165 50323

    Honolulu, Hawaii

  • Ep0165 50512

    Boise, Idaho

  • Ep0165 50493

    Chicago, Illinois

  • Ep0165 50504

    Fort Wayne, Indiana

  • Ep0165 50517

    New Orleans, Louisiana

  • Ep0165 50615

    Boston, Massachusetts

  • Ep0165 50047

    Boston, Massachusetts

  • Ep0165 50507

    St Louis, Missouri

  • Ep0165 50299

    New Brunswick, New Jersey

  • Ep0165 50497

    Amherst, New York

  • Ep0165 50298

    New York, New York

  • Ep0165 50490

    New York, New York

  • Ep0165 50518

    New York, New York

  • Ep0165 50034

    Rochester, New York

  • Ep0165 50514

    Charlotte, North Carolina

  • Ep0165 50715

    Durham, North Carolina

  • Ep0165 50701

    Portland, Oregon

  • Ep0165 50096

    Philadelphia, Pennsylvania

  • Ep0165 50364

    Philadelphia, Pennsylvania

  • Ep0165 50089

    Philadelphia, Pennsylvania

  • Ep0165 50511

    Pittsburgh, Pennsylvania

  • Ep0165 50491

    Pittsburgh, Pennsylvania

  • Ep0165 50700

    Chattanooga, Tennessee

  • Ep0165 50513

    Memphis, Tennessee

  • Ep0165 50103

    Nashville, Tennessee

Showing 40 of 133 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.